Conditions: Autosomal Dominant Polycystic Kidney Disease
Keywords: ADPKD Tolvaptan OPC-41061
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 13
Healthy volunteers: no

Brief summary:
ADPKD patients who were enrolled in Study 156-05-002 will receive repeated oral administration of OPC-41061 at doses of 15 mg twice daily (morning and evening). Administration will be continued until the time of manufacturing and distribution approval of OPC-41061 for ADPKD in Japan.

Detailed description:

Arms:
arm 1: Repeated oral administration at doses of 15 mg twice daily (morning and evening)

Interventions: intervention 1: OPC-41061
Intervention descriptions: intervention 1: Repeated oral administration at doses of 15 mg twice daily (morning and evening)

Protocol document: